To investigate the prevalence of preoperative hypercoagulability assessed by thromboelastography (TEG), to identify patient characteristics associated with hypercoagulability and to explore whether hypercoagulability is associated with a greater risk for myocardial infarction (MI), stroke and mortality 30 days after coronary artery bypass grafting (CABG) surgery.
INTRODUCTION
Hypercoagulability, evidenced by increased clot strength by thromboelastography (TEG), and its role in postoperative/postinterventional thromboembolic events are currently under intense investigation. Hypercoagulability is implicated in the pathogenesis of thromboembolic events such as myocardial infarction (MI), ischaemic stroke, pulmonary embolus and deep vein thrombosis (DVT) [1] [2] [3] [4] .
We have reported that TEG-hypercoagulability is more prevalent in cardiac surgery patients than in healthy blood donors as evidenced by our finding that 6 of 22 patients (27%) referred to coronary artery bypass grafting (CABG) surgery demonstrated TEG-hypercoagulability vs. only 1 of 43 healthy blood donors (2%) (P = 0.005) [4] .
In a mixed non-cardiac surgery patient group, postoperative hypercoagulability identified with TEG was associated with a significantly higher rate of postoperative thromboembolic complications, including MI, compared with normocoagulable patients [1] . Another study found that, in a population with coronary artery disease undergoing percutaneous coronary intervention (PCI), hypercoagulability demonstrated by TEG was a novel risk factor for post-procedure ischaemic events [2] . This is further corroborated by a recent study, demonstrating that TEG-hypercoagulability in patients undergoing nonemergent PCI is not only associated with thromboembolic complications, but also occurs significantly more often in diabetic patients [5] . It is, however, not presently clear which risk factors that contribute to or are associated with development of hypercoagulability.
The aim of this study was to evaluate the prevalence of TEG-hypercoagulability (identified by increased clot strength) in a population of CABG patients and to investigate patient characteristics associated with this. Furthermore, we also investigated whether TEG-hypercoagulability was associated with patient outcome by assessing a combined endpoint of MI, stroke and mortality at 30 days after surgery.
MATERIALS AND METHODS
Patient characteristics and blood samples were obtained preoperatively, on the day before surgery, from 200 consecutive patients, undergoing an isolated CABG procedure at our institution in the period October 2008-April 2009. All patients were >18 years old. There were no exclusion criteria. Data were collected prospectively; outcome data were obtained from the regional hospital database or, in a few cases, by telephonic contact with the patient. The study design was observational and was conducted in concordance with the Helsinki 2 declaration. All patients gave informed consent upon admission, and the local ethics committee approved the study.
Blood sampling and thromboelastography analysis
For TEG analysis, whole blood was collected in a 3.2% trisodium citrate vacutainer (Greiner Bio-One, Kremsmünster, Austria) and analysed 90 min after collection using a computerized TEG coagulation analyser (TEG model 5000; Haemoscope Corporation, Niles, IL, USA). The coagulation process in the assay was initiated using kaolin as the activator.
TEG provides an evaluation of the viscoelastic properties of the clot, in whole blood, thus generating a complete overview of clot dynamics from clot initiation, clot formation and clot strength as well as fibrinolysis (Fig. 1) [6, 7] . Maximum amplitude (MA) of the TEG tracing represents the maximum clot strength, with the upper normal reference for MA being 69 mm according to the manufacturer. TEG-hypercoagulability was consequently defined as an MA of ≥69 mm.
Surgical technique
All CABG procedures were performed through median sternotomy. One hundred and ninety-eight procedures were performed on-pump with cardiopulmonary bypass and extracorporal circulation (ECC); only two procedures were performed off-pump. Patients on ECC were heparinized to maintain an activated clotting time of >480 s, and this was reversed with protaminesulphate (1:1) after finalization of ECC. All patients on ECC received a total of 4 g tranexamic acid during surgery.
Perioperative antithrombotic therapy
Routinely, aspirin and clopidogrel were discontinued 5 days before surgery; in acute coronary syndrome patients, Clexane (Enoxaparin, a low-molecular-weight heparin (LMWH)) 40 mg was administered subcutaneously twice a day. Some patients in the later study period received inj. Arixtra (Fondaparinux) 2.5 mg once daily instead of Clexane. After surgery, only off-pump patients received Clexane 40 mg s.c. twice daily until discharge from the hospital, and all other patients did not receive LMWH after CABG. Aspirin 75 mg orally was commenced 6-24 h after surgery, and if clopidogrel was administered after surgery, then it was usually started on the second postoperative day (in a 75 mg/day oral dose).
Outcome data
Perioperative data were collected from the central operation registry (PATS-Patient Analysis and Tracking System) in which detailed data of every single operation at our institution are registered. Here, detailed descriptions of the operations are carried out, including perfusion/ECC data and postoperative complications. Outcome data were collected from the regional hospital database, which is based on the Danish Central Person Registry (CPR). Every citizen in Denmark has a unique CPR number. Therefore, all hospital contacts, including admission in the uptake area and death, are registered in the regional hospital database, and based on the person's unique CPR number, ensure a high data validity. For those patients living outside the uptake area, the information was collected via the telephonic contact. The specific data collected were any admissions with MI, stroke and/or death from all causes. MI was defined as creatine kinase MB levels >80 U/l in the immediate postoperative period, and coronary angiography was performed to confirm diagnosis. MI after discharge from our institution was defined as two out of the following three: chest pain, signs of new infarction on electrocardiogram or relevant biomarker elevation. Stroke was defined as neurological deficits lasting for >24 h.
Collection of outcome data was done blinded to the coagulation status.
Statistical analysis
For categorical variables, χ 2 tests or Fisher's exact test were used as appropriate. For continuous variables, analysis was performed with the two-sample t-test, after ensuring normal distribution of the data. Data with no normal distribution were analysed by Wilcoxon's rank-sum test. Univariate and multivariate logistic regression analyses were performed to identify patient characteristics associated with either TEG-hypercoagulability or combined 30-day event rate. Continuous variables are presented as mean ± standard deviation (SD) unless otherwise noted. P-values <0.05 were considered statistically significant. In tables, all P-values >0.10 are denoted non-significant. All statistical analyses were performed using PASW (SPSS) statistical software v.18.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS
A total of 200 patients were consecutively included in the study. Additionally, 42 patients failed to be included, primarily due to logistics (i.e. blood samples not obtained the day before surgery), and some patients being transferred directly to surgery from the cardiology department on the day of surgery, and these were not included in further analyses of the study. Furthermore, postoperative 30-day outcome data for six patients could not be retrieved, but they were not excluded from the study with respect to screening data. Eighty-seven out of 200 patients (43.5%) demonstrated TEG-hypercoagulability. The majority of women, 25 out of 41 (61%), were hypercoagulable. TEG-hypercoagulable patients were significantly older, more often had hypertension and severe chronic obstructive pulmonary disease and hence EuroSCORE was also higher in the hypercoagulable group. Diabetes demonstrated a trend towards being significantly more prevalent in TEG-hypercoagulable patients (P = 0.055; see Table 1 for patient characteristics).
TEG parameters demonstrated significantly shortened reaction time and increased angle values in hypercoagulable patients. Furthermore, fibrinogen levels, platelet count and C-reactive protein (CRP) were significantly elevated in hypercoagulable patients. Plasma-based conventional coagulation tests such as activated partial thrombin time (APTT) and international normalized ratio (INR) did not demonstrate significantly different results between the two groups. Laboratory data are presented in Table 2 . For perioperative data, see Table 3 .
The 30-day combined event rate of MI, stroke and mortality was significantly higher in the TEG-hypercoagulable group (17.2 vs. 6.6%, P = 0.019). These events occurred in a total of 22 patients, of whom five had postoperative atrial fibrillation and one was re-operated for bleeding. It is worth to note that TEG-hypercoagulable patients were significantly more often on postoperative dual antiplatelet therapy with clopidogrel in addition to aspirin (23 vs. 5.6%, P < 0.001). Postoperative outcome data are presented in Table 4 .
Univariate logistic regression for patient factors associated with TEG-hypercoagulability revealed higher age, female gender, hypertension, severe chronic obstructive pulmonary disease (COPD), higher platelet count and higher fibrinogen level as significant risk factors associated with TEG-hypercoagulability. A multivariate logistic regression model demonstrated that higher age, platelet count and fibrinogen were independently associated with TEG-hypercoagulability (Table 5) .
In a univariate logistic model for combined 30-day event, only TEG-hypercoagulability and female gender were significantly [8] . By multivariate regression analysis, only female gender was significantly associated with the 30-day combined event rate, with TEG-hypercoagulability demonstrating a trend (P = 0.065). In this analysis, postoperative atrial fibrillation and re-operation for bleeding did not have impact on the 30-day outcome.
DISCUSSION
In the present study, 43.5% of patients scheduled for CABG surgery presented with TEG-hypercoagulability, with higher age, higher platelet count and fibrinogen being independently associated with a hypercoagulable state, and these patients had a higher 30-day event rate. TEG-hypercoagulability and female gender were univariate predictors of the combined 30-day event rate, whereas only female gender was an independent predictor of this outcome. A prevalence of preoperative TEG-hypercoagulability in 43.5% of CABG patients is in alignment with the prevalence in patients undergoing PCI, where Gurbel et al. [5] reported that 49% of the patients demonstrated TEG-hypercoagulability.
The majority of the female CABG patients presented with TEG-hypercoagulability (61%) and this is in alignment with Roeloffzen et al. [9] who recently reported that female gender together with increased age is associated with increased coagulability in healthy middle-aged individuals. Theusinger et al. [10] also found that increasing age and female gender are associated with hypercoagulability. It is interesting that female gender empirically has added to postoperative 30-day mortality risk after cardiac surgery, in such a degree that female gender alone adds 1 point to the EuroSCORE. In the present study, female gender was the best predictor for 30-day combined event risk, together with TEG-hypercoagulability. It could be speculated that since the majority of the female patients are hypercoagulable, this may be an important cause of their higher mortality risk after surgery.
Hypertension, diabetes mellitus and dyslipidaemia are the constituents of the metabolic syndrome [11] and it is debated whether the syndrome is just the sum of individual risk factors or whether the combination yields a greater risk for cardiovascular disease and events. Interestingly, diabetes has previously been strongly correlated with TEG-hypercoagulability [5] and our study found a near-significant difference in diabetes prevalence between the TEG-hypercoagulable group and the normocoagulable patients. Hypertension was significantly more prevalent in TEG-hypercoagulable patients. Furthermore, CRP has also been implicated in the metabolic syndrome, both as a risk marker and as a promoter of atherogenesis [11] . The procoagulant effects of CRP are believed to be mediated by stimulating tissue factor release, by direct interaction with the endovascular glycocalyx and by reducing fibrinolysis [11] [12] [13] . Tantry et al. [13] reported that inflammatory markers, such as CRP, are closely related to progression in cardiovascular disease and a more procoagulable state. In alignment with this, the TEG-hypercoagulable patients in the present study demonstrated significantly higher CRP levels than TEG-normocoagulable patients. Future studies must elucidate whether indeed the cluster of diseases in the metabolic syndrome induces a hypercoagulable state and thereby increases the risk for postoperative thromboembolic events in these patients.
In the present study postoperative atrial fibrillation after CABG and re-operation for bleeding did not demonstrate any significant impact on the 30-day event rate in multivariate analysis, but this may be due to the small study population.
Our outcome results showed that all events (MI, stroke and allcause mortality) on their own occurred more often in TEG-hypercoagulable patients, both in crude numbers and in percentages, though not reaching statistical significance, which may be due to the limited number of patients studied. The combined 30-day event rate of MI, stroke and mortality was higher in TEG-hypercoagulable patients than in TEG-normocoagulable patients. These findings that hypercoagulable patients have higher rates of thromboembolic complications and death are in concordance with earlier findings by Gurbel et al. [2] in PCI patients, McCrath et al. [1] in a diverse non-cardiac surgery group and Kashuk et al. [3] in critically ill ICU patients. We, for the first time, demonstrate that the hypercoagulable status before CABG, identified by TEG, does yield a greater risk for thromboembolic complications and death after surgery. This enables the clinician to identify patients at high risk for thromboembolic complications and thereby tailor individualized postoperative antithrombotic therapy. Randomized clinical trials (RCTs) are needed to elucidate whether intensified antiplatelet therapy after surgery reduces this risk. We are currently conducting such an RCT, the TEG-CABG trial (Clinicaltrials.gov identifier: NCT01046942), which hopefully will address some of the issues discussed here.
Our results are, significantly biased towards fewer events in the TEG-hypercoagulable group, as more patients in this group were on dual antiplatelet therapy with clopidogrel in addition to aspirin postoperatively when compared with normocoagulable patients (23 vs. 6%, P < 0.001). Dual antiplatelet therapy has in patients with acute coronary syndromes and post-PCI proved to significantly reduce cardiovascular events and death [14] [15] [16] . Although guidelines from ECS/EACTS now recommend clopidogrel in addition to aspirin after CABG in post-MI patients, to date no RCT has investigated this hypothesis, and Cochrane reviewers do not support dual antiplatelet therapy after surgical revascularization in post-MI patients [14, 16, 17] . At our institution we do not automatically add clopidogrel as antithrombotic therapy after CABG post-non-ST-elevation MI; as discussed above, there is no evidence for this practice. The difference in dual antiplatelet therapy between the two groups is mainly explained because of our great interest in TEG-hypercoagulability and the desire to prevent thromboembolic complications in this high-risk patient population.
LIMITATIONS
Besides the limitations of the observational design of this study, we did not examine postoperative infections, ICU stay, days in ventilator, haemodialysis, transfusions etc., which could increase the risk for MI, stroke and death. The postoperative coagulation status including TEG was also not taken into consideration. The study size of 200 patients is small and also a limitation; however, it is comparable to the other studies examining TEG-hypercoagulability. Perioperative and outcome data were collected from validated databases, which is also a limitation.
CONCLUSIONS
We found that 43.5% of CABG patients were TEG-hypercoagulable and we identified several factors that relate to such a state preoperatively. The findings of the present study support that TEG-hypercoagulable patients are at higher risk for thromboembolic complications after surgery. Further studies are required to investigate the relationship between hypercoagulability and thromboembolic risk postoperatively, and whether this risk can be minimized with intensified antiplatelet therapy.
